Enrique Poradosu

This profile gathers the share dealings of Enrique Poradosu in Nuvectis Pharma, Inc. In total, 12 filings cover trades dated from 4 February 2022 to 6 January 2026.

Every open-market trade on record is a purchase: 7 purchases worth €41k, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 5 share grants.

A typical purchase (the median) is worth €5,261. 7 out of 7 purchases came within 30 days of a purchase by at least one other insider of the same company. Purchases made close together by different insiders form what is called a cluster.

The latest filing, published on 9 January 2026, reports a share grant in Nuvectis Pharma, Inc. The clock since the last published purchase (20 November 2024) now reads 719 days. Typically, a trade is published a median of 3 days after it takes place. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.